This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
Pneumococcal Plain Polysaccharide Vaccine and Conjugate Vaccine
Case-control and observational studies provide the majority of information pertaining to the protection afforded by PPSV23. Lower efficacy was reported in a widely referenced case control study in the United States of 983 IPD cases in which PPSV23 demonstrated 61% efficacy (95% CI, 47-72) in immunocompetent adults.1 In immunocompromised persons, the vaccine-type efficacy was much lower at 21% (95% CI, −55 to 60) and not statistically significant.2
Polysaccharide vaccines generally induce only short-term immunity, and do not elicit memory-boosting responses, and are not effective in the elicitation of immune responses in children aged <2 years. These characteristics are associated with an immune response elicited primarily by B-cells in secreting IgM.3
In this type of a response, polysaccharide(s) interact directly with B-cells and activate them expressing surface IgM antibodies specific to pneumococcal serotype-specific polysaccharide(s). The response to pneumococcal polysaccharides is independent of the dedicated antigen
presenting cells or T lymphocyte help. The absence of their involvement prevents the induction of an IgM to IgG antibody switch and the formation of memory B-cells (see figure below).3
Differences Between Plain Polysaccharide and Protein-polysaccharide Conjugate Vaccines4-6,7-9
CI, confidence interval; IPD, invasive pneumococcal disease; IgG, immunoglobulin G; IgM, immunoglobulin M; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.